GentiBio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
61
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$157M
- Investors
-
8
GentiBio General Information
Description
Developer of a modular engineering platform designed to develop therapies to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company's proprietary autologous and allogeneic platform integrates key complementary technologies needed to restore immune tolerance and overcome limitations in existing regulatory T-cell therapeutics, enabling healthcare providers to address the fundamental cause of many diseases that result from overshooting and malfunctioning of the immune system.
Contact Information
Website
www.gentibio.comCorporate Office
- 150 Cambridgepark Drive
- 9th Floor
- Cambridge, MA 02140
- United States
Corporate Office
- 150 Cambridgepark Drive
- 9th Floor
- Cambridge, MA 02140
- United States
GentiBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 11-Aug-2021 | $157M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 05-Aug-2020 | Completed | Pre-Clinical Trials |
GentiBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GentiBio Comparisons
Industry
Financing
Details
GentiBio Competitors (3)
One of GentiBio’s 3 competitors is Quell Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quell Therapeutics | Venture Capital-Backed | London, United Kingdom | ||||
| Sonoma Biotherapeutics | Venture Capital-Backed | San Francisco, CA | ||||
| Lava Therapeutics | Formerly VC-backed | Utrecht, Netherlands |
GentiBio Patents
GentiBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213230-A1 | Chimeric t cell receptors targeting butyrophilin-like proteins | Pending | 31-Mar-2025 | ||
| WO-2026060042-A1 | Membrane-anchored nk cell inhibitory receptor engagers | Pending | 10-Sep-2024 | ||
| WO-2026035928-A1 | Regulatory t cells expressing chimeric antigen receptors | Pending | 07-Aug-2024 | ||
| EP-4654981-A1 | Engineered repair regulatory t cells | Pending | 27-Jan-2023 | ||
| JP-2026503660-A | Engineered repair regulatory t cells | Pending | 27-Jan-2023 | C12N5/0637 |
GentiBio Signals
GentiBio Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avidity Partners | Asset Manager | Minority | ||
| Benaroya Research Institute | Corporation | Minority | ||
| Matrix Capital Management | Hedge Fund | Minority | ||
| Seattle Children's Hospital | Corporation | Minority | ||
| T1D Fund | Venture Capital | Minority |
GentiBio FAQs
-
When was GentiBio founded?
GentiBio was founded in 2020.
-
Where is GentiBio headquartered?
GentiBio is headquartered in Cambridge, MA.
-
What is the size of GentiBio?
GentiBio has 61 total employees.
-
What industry is GentiBio in?
GentiBio’s primary industry is Drug Discovery.
-
Is GentiBio a private or public company?
GentiBio is a Private company.
-
What is the current valuation of GentiBio?
The current valuation of GentiBio is .
-
What is GentiBio’s current revenue?
The current revenue for GentiBio is .
-
How much funding has GentiBio raised over time?
GentiBio has raised $177M.
-
Who are GentiBio’s investors?
Avidity Partners, Benaroya Research Institute, Matrix Capital Management, Seattle Children's Hospital, and T1D Fund are 5 of 8 investors who have invested in GentiBio.
-
Who are GentiBio’s competitors?
Quell Therapeutics, Sonoma Biotherapeutics, and Lava Therapeutics are competitors of GentiBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process